What's Happening?
A recent survey by the International Foundation of Employee Benefit Plans (IFEBP) reveals that most U.S. employers are not expanding coverage for GLP-1 drugs used for weight loss, despite their increasing availability and Medicare's new coverage policies.
The survey, conducted in June 2026, included nearly 300 employer health plans and found that only 36% of employers cover GLP-1s for both diabetes and weight loss, a figure unchanged from 2025. The reluctance to expand coverage is primarily due to the high costs associated with these drugs, which have seen a significant rise in demand. Instead, employers are exploring alternative ways to support employee health, such as encouraging the use of direct-to-consumer platforms and flexible spending accounts for these treatments.
Why It's Important?
The decision by employers to limit coverage of GLP-1 drugs has significant implications for the healthcare industry and employees. As these drugs account for a growing percentage of annual claims, the financial burden on health plans is substantial. Employers are cautious about the high costs, which could impact their ability to offer comprehensive health benefits. This situation highlights the broader challenge of balancing cost management with employee health needs. The limited coverage could also affect the pharmaceutical market, particularly for companies like Eli Lilly and Novo Nordisk, which produce these drugs. Additionally, the lack of widespread coverage may hinder efforts to address obesity, a major public health issue in the U.S.
What's Next?
Future changes in employer coverage of GLP-1 drugs may depend on evidence showing that these drugs can reduce overall healthcare costs by decreasing the need for other medical interventions, such as surgeries. The ongoing Medicare program covering GLP-1s for obesity could provide valuable data on potential cost savings. Employers may reconsider their coverage policies if these drugs demonstrate significant long-term benefits. Meanwhile, around 9% of employers are contemplating adopting coverage for obesity, indicating a potential shift in the future. Stakeholders will closely monitor the outcomes of the Medicare program and any emerging data on cost-effectiveness.
